NO327713B1 - Sammensetninger for reduksjon av okulaer hypertensjon og anvendelse av sammensetning - Google Patents

Sammensetninger for reduksjon av okulaer hypertensjon og anvendelse av sammensetning Download PDF

Info

Publication number: NO327713B1
Authority: NO; Norway
Prior art keywords: composition according; preservative; weight; prostaglandin; composition
Prior art date: 1997-03-17

Application number

NO19994481A

Other languages

English (en)

Norwegian (no)

Other versions

NO994481D0 (no

NO994481L (no

Inventor

Mary Sou

Shau-Fong Yen

Kenneth W Reed

Regina Flinn Peacock

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-17

Filing date

1999-09-16

Publication date

2009-09-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO327713(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-16 Application filed by Novartis Ag filed Critical Novartis Ag

1999-09-16 Publication of NO994481D0 publication Critical patent/NO994481D0/no

1999-09-16 Publication of NO994481L publication Critical patent/NO994481L/no

2009-09-14 Publication of NO327713B1 publication Critical patent/NO327713B1/no

Links

239000000203 mixture Substances 0.000 title claims abstract description 172
206010030043 Ocular hypertension Diseases 0.000 title claims description 8
239000003755 preservative agent Substances 0.000 claims abstract description 85
150000003180 prostaglandins Chemical class 0.000 claims abstract description 76
230000002335 preservative effect Effects 0.000 claims abstract description 75
239000013543 active substance Substances 0.000 claims abstract description 57
XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims abstract description 50
239000003795 chemical substances by application Substances 0.000 claims abstract description 36
239000002736 nonionic surfactant Substances 0.000 claims abstract description 29
239000002207 metabolite Substances 0.000 claims abstract description 12
239000004094 surface-active agent Substances 0.000 claims description 50
-1 fatty acid esters Chemical class 0.000 claims description 46
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 44
229920000053 polysorbate 80 Polymers 0.000 claims description 44
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 42
229940068968 polysorbate 80 Drugs 0.000 claims description 42
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 40
229960000686 benzalkonium chloride Drugs 0.000 claims description 39
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical class [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 39
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 25
229930195725 Mannitol Natural products 0.000 claims description 25
239000000594 mannitol Substances 0.000 claims description 25
235000010355 mannitol Nutrition 0.000 claims description 25
229940094443 oxytocics prostaglandins Drugs 0.000 claims description 19
150000003839 salts Chemical class 0.000 claims description 17
238000004321 preservation Methods 0.000 claims description 13
239000000872 buffer Substances 0.000 claims description 12
239000003623 enhancer Substances 0.000 claims description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
239000002738 chelating agent Substances 0.000 claims description 9
235000014113 dietary fatty acids Nutrition 0.000 claims description 9
239000000194 fatty acid Substances 0.000 claims description 9
229930195729 fatty acid Natural products 0.000 claims description 9
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
229920001214 Polysorbate 60 Polymers 0.000 claims description 7
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 6
150000005215 alkyl ethers Chemical class 0.000 claims description 6
229920001223 polyethylene glycol Polymers 0.000 claims description 6
229920001451 polypropylene glycol Polymers 0.000 claims description 6
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims description 5
MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 claims description 5
LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 claims description 5
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 4
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
150000001875 compounds Chemical class 0.000 claims description 4
229960003540 oxyquinoline Drugs 0.000 claims description 4
150000002978 peroxides Chemical class 0.000 claims description 4
MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims description 4
159000000000 sodium salts Chemical class 0.000 claims description 4
239000000600 sorbitol Substances 0.000 claims description 4
238000003860 storage Methods 0.000 claims description 4
MKNJWAXSYGAMGJ-UHFFFAOYSA-N (2,3,4,5,6-pentachlorophenyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl MKNJWAXSYGAMGJ-UHFFFAOYSA-N 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
229920000136 polysorbate Polymers 0.000 claims description 3
229910052700 potassium Inorganic materials 0.000 claims description 3
239000011591 potassium Substances 0.000 claims description 3
125000001453 quaternary ammonium group Chemical group 0.000 claims description 3
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 3
VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims description 2
229940015297 1-octanesulfonic acid Drugs 0.000 claims description 2
SVPKNMBRVBMTLB-UHFFFAOYSA-N 2,3-dichloronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(Cl)=C(Cl)C(=O)C2=C1 SVPKNMBRVBMTLB-UHFFFAOYSA-N 0.000 claims description 2
NCKMMSIFQUPKCK-UHFFFAOYSA-N 2-benzyl-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1CC1=CC=CC=C1 NCKMMSIFQUPKCK-UHFFFAOYSA-N 0.000 claims description 2
VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 claims description 2
RNWWSUJDJOHADM-UHFFFAOYSA-N 2-chloro-6-pentylphenol Chemical compound CCCCCC1=CC=CC(Cl)=C1O RNWWSUJDJOHADM-UHFFFAOYSA-N 0.000 claims description 2
WBIQQQGBSDOWNP-UHFFFAOYSA-N 2-dodecylbenzenesulfonic acid Chemical class CCCCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O WBIQQQGBSDOWNP-UHFFFAOYSA-N 0.000 claims description 2
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
229940061334 2-phenylphenol Drugs 0.000 claims description 2
VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical class C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 claims description 2
LZUKCYHMVDGDBK-UHFFFAOYSA-N 4-chloro-2-cyclopentylphenol Chemical compound OC1=CC=C(Cl)C=C1C1CCCC1 LZUKCYHMVDGDBK-UHFFFAOYSA-N 0.000 claims description 2
OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 claims description 2
WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 claims description 2
150000005168 4-hydroxybenzoic acids Chemical class 0.000 claims description 2
QHPQWRBYOIRBIT-UHFFFAOYSA-N 4-tert-butylphenol Chemical compound CC(C)(C)C1=CC=C(O)C=C1 QHPQWRBYOIRBIT-UHFFFAOYSA-N 0.000 claims description 2
239000005725 8-Hydroxyquinoline Substances 0.000 claims description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
229930185605 Bisphenol Natural products 0.000 claims description 2
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 2
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 2
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 2
SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 claims description 2
229910019142 PO4 Inorganic materials 0.000 claims description 2
108010093965 Polymyxin B Proteins 0.000 claims description 2
239000003568 Sodium, potassium and calcium salts of fatty acids Chemical class 0.000 claims description 2
150000001298 alcohols Chemical class 0.000 claims description 2
150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 claims description 2
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 2
229960001950 benzethonium chloride Drugs 0.000 claims description 2
229960001574 benzoxonium chloride Drugs 0.000 claims description 2
235000019445 benzyl alcohol Nutrition 0.000 claims description 2
150000001642 boronic acid derivatives Chemical class 0.000 claims description 2
229960003260 chlorhexidine Drugs 0.000 claims description 2
229960004926 chlorobutanol Drugs 0.000 claims description 2
229960005443 chloroxylenol Drugs 0.000 claims description 2
229960003405 ciprofloxacin Drugs 0.000 claims description 2
229960003887 dichlorophen Drugs 0.000 claims description 2
229940060296 dodecylbenzenesulfonic acid Drugs 0.000 claims description 2
ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 claims description 2
230000002708 enhancing effect Effects 0.000 claims description 2
150000002731 mercury compounds Chemical class 0.000 claims description 2
WUOSYUHCXLQPQJ-UHFFFAOYSA-N n-(3-chlorophenyl)-n-methylacetamide Chemical compound CC(=O)N(C)C1=CC=CC(Cl)=C1 WUOSYUHCXLQPQJ-UHFFFAOYSA-N 0.000 claims description 2
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims description 2
235000010292 orthophenyl phenol Nutrition 0.000 claims description 2
NRZWYNLTFLDQQX-UHFFFAOYSA-N p-tert-Amylphenol Chemical compound CCC(C)(C)C1=CC=C(O)C=C1 NRZWYNLTFLDQQX-UHFFFAOYSA-N 0.000 claims description 2
229940090668 parachlorophenol Drugs 0.000 claims description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
150000002989 phenols Chemical class 0.000 claims description 2
229960005323 phenoxyethanol Drugs 0.000 claims description 2
229940067107 phenylethyl alcohol Drugs 0.000 claims description 2
235000021317 phosphate Nutrition 0.000 claims description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
229920000728 polyester Polymers 0.000 claims description 2
229960003548 polymyxin b sulfate Drugs 0.000 claims description 2
229950008882 polysorbate Drugs 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
PXGPLTODNUVGFL-JZFBHDEDSA-N prostaglandin F2beta Chemical class CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-JZFBHDEDSA-N 0.000 claims description 2
150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 2
235000013875 sodium salts of fatty acid Nutrition 0.000 claims description 2
LUKFIMQJXRYJNK-UHFFFAOYSA-L sodium;ethyl-(4-sulfonatophenyl)sulfanylmercury Chemical compound [Na+].CC[Hg]SC1=CC=C(S([O-])(=O)=O)C=C1 LUKFIMQJXRYJNK-UHFFFAOYSA-L 0.000 claims description 2
229940006295 sulfonated oleic acid Drugs 0.000 claims description 2
239000003784 tall oil Chemical class 0.000 claims description 2
229940033663 thimerosal Drugs 0.000 claims description 2
229960001484 edetic acid Drugs 0.000 claims 4
239000002220 antihypertensive agent Substances 0.000 claims 1
150000002888 oleic acid derivatives Chemical class 0.000 claims 1
229950008081 unoprostone isopropyl Drugs 0.000 abstract description 49
230000004410 intraocular pressure Effects 0.000 abstract description 23
230000002829 reductive effect Effects 0.000 abstract description 11
230000006872 improvement Effects 0.000 abstract description 8
239000000654 additive Substances 0.000 abstract description 7
230000009467 reduction Effects 0.000 abstract description 6
208000010412 Glaucoma Diseases 0.000 abstract description 5
238000009472 formulation Methods 0.000 description 62
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 36
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 34
239000000243 solution Substances 0.000 description 28
238000000034 method Methods 0.000 description 21
239000011780 sodium chloride Substances 0.000 description 18
238000012360 testing method Methods 0.000 description 12
241000589516 Pseudomonas Species 0.000 description 10
QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 8
230000008901 benefit Effects 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
239000012153 distilled water Substances 0.000 description 6
239000008389 polyethoxylated castor oil Substances 0.000 description 6
239000003814 drug Substances 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
239000012530 fluid Substances 0.000 description 5
230000007794 irritation Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
206010015946 Eye irritation Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000003715 calcium chelating agent Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000006196 drop Substances 0.000 description 3
230000004406 elevated intraocular pressure Effects 0.000 description 3
231100000013 eye irritation Toxicity 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
150000000258 13,14-dihydro-15-keto-prostaglandin D2 derivatives Chemical class 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical class CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical class NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
208000007950 Ocular Hypotension Diseases 0.000 description 2
206010052143 Ocular discomfort Diseases 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
229920002675 Polyoxyl Polymers 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical class NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
229910021538 borax Inorganic materials 0.000 description 2
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
239000004327 boric acid Substances 0.000 description 2
235000010338 boric acid Nutrition 0.000 description 2
239000011575 calcium Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
229960005091 chloramphenicol Drugs 0.000 description 2
150000001860 citric acid derivatives Chemical class 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000008029 eradication Effects 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000000644 isotonic solution Substances 0.000 description 2
150000003893 lactate salts Chemical class 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
235000021309 simple sugar Nutrition 0.000 description 2
229960001922 sodium perborate Drugs 0.000 description 2
235000010339 sodium tetraborate Nutrition 0.000 description 2
YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
VPJXQGSRWJZDOB-UHFFFAOYSA-O 2-carbamoyloxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCOC(N)=O VPJXQGSRWJZDOB-UHFFFAOYSA-O 0.000 description 1
XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
239000004472 Lysine Chemical class 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical class CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
235000021319 Palmitoleic acid Nutrition 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
229920000289 Polyquaternium Polymers 0.000 description 1
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
125000002723 alicyclic group Chemical group 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
235000020661 alpha-linolenic acid Nutrition 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940055075 anticholinesterase parasympathomimetics Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
229960002836 biphenylol Drugs 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229960004484 carbachol Drugs 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
229960001927 cetylpyridinium chloride Drugs 0.000 description 1
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical class [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
229960003291 chlorphenamine Drugs 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical class NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
RWZVPVOZTJJMNU-UHFFFAOYSA-N demarcarium Chemical compound C=1C=CC([N+](C)(C)C)=CC=1OC(=O)N(C)CCCCCCCCCCN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 RWZVPVOZTJJMNU-UHFFFAOYSA-N 0.000 description 1
229960004656 demecarium Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
239000005555 hypertensive agent Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
229960004488 linolenic acid Drugs 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000003604 miotic agent Substances 0.000 description 1
239000003595 mist Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
150000002889 oleic acids Chemical class 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 description 1
229960002516 physostigmine salicylate Drugs 0.000 description 1
229960001416 pilocarpine Drugs 0.000 description 1
229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002994 raw material Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 description 1
CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005207 tetraalkylammonium group Chemical class 0.000 description 1
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000012443 tonicity enhancing agent Substances 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Ophthalmology & Optometry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO19994481A 1997-03-17 1999-09-16 Sammensetninger for reduksjon av okulaer hypertensjon og anvendelse av sammensetning NO327713B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US81922197A	1997-03-17	1997-03-17
PCT/EP1998/001483 WO1998041208A1 (en)	1997-03-17	1998-03-13	Compositions and methods for reducing ocular hypertension

Publications (3)

Publication Number	Publication Date
NO994481D0 NO994481D0 (no)	1999-09-16
NO994481L NO994481L (no)	1999-09-16
NO327713B1 true NO327713B1 (no)	2009-09-14

Family

ID=38729083

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19994481A NO327713B1 (no)	1997-03-17	1999-09-16	Sammensetninger for reduksjon av okulaer hypertensjon og anvendelse av sammensetning

Country Status (33)

Country	Link
EP (1)	EP0969846B2 (xx)
JP (2)	JP4920124B2 (xx)
KR (1)	KR100555818B1 (xx)
CN (1)	CN1236775C (xx)
AR (2)	AR002194A1 (xx)
AT (1)	ATE257385T1 (xx)
AU (1)	AU738781B2 (xx)
BR (2)	BRPI9816218B1 (xx)
CA (1)	CA2280089C (xx)
CL (1)	CL2009001870A1 (xx)
CO (1)	CO4940427A1 (xx)
CY (1)	CY2526B1 (xx)
CZ (1)	CZ299833B6 (xx)
DE (1)	DE69820997T3 (xx)
DK (1)	DK0969846T4 (xx)
EE (1)	EE04091B1 (xx)
ES (1)	ES2214706T5 (xx)
HK (1)	HK1026841A1 (xx)
HU (1)	HU228896B1 (xx)
ID (1)	ID22389A (xx)
IL (1)	IL131041A0 (xx)
MY (1)	MY122237A (xx)
NO (1)	NO327713B1 (xx)
NZ (1)	NZ337322A (xx)
PE (1)	PE61899A1 (xx)
PL (1)	PL197509B1 (xx)
PT (1)	PT969846E (xx)
RU (1)	RU2197970C2 (xx)
SI (1)	SI0969846T2 (xx)
TW (1)	TW527187B (xx)
UA (1)	UA63938C2 (xx)
WO (1)	WO1998041208A1 (xx)
ZA (1)	ZA982188B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6011062A (en) *	1994-12-22	2000-01-04	Alcon Laboratories, Inc.	Storage-stable prostaglandin compositions
AR002194A1 (es) *	1997-03-17	1998-01-07	Sanchez Reynaldo Alemany	Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) *	1998-06-17	2001-02-13	Pharmacia & Upjohn Company	Prostaglandins formulation and process
JP4880808B2 (ja) *	1999-11-15	2012-02-22	久光製薬株式会社	人工涙液型点眼剤組成物
TWI290470B (en) *	1999-12-01	2007-12-01	Sankyo Co	The composition for treating glaucoma
EP1321144B1 (en) *	2000-09-13	2010-12-08	Santen Pharmaceutical Co., Ltd.	Eye drops
WO2002045748A1 (fr) *	2000-12-05	2002-06-13	Sankyo Company, Limited	Compositions d'abaissement de la tension oculaire pour administration topique
US20020198209A1 (en) *	2001-05-03	2002-12-26	Allergan Sales Inc.	Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) *	2002-10-24	2006-07-11	Sucampo Ag (Usa) Inc.	Method for treating ocular hypertension and glaucoma
KR101206319B1 (ko) *	2004-03-18	2012-11-29	가부시키가이샤 아루떼꾸 우에노	티아졸 유도체를 포함하는 수성 조성물
US8569367B2 (en) *	2004-11-16	2013-10-29	Allergan, Inc.	Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) *	2005-01-20	2005-03-02	Resolution Chemicals Ltd	Stable prostaglandin-containing compositions
US7851504B2 (en) *	2005-03-16	2010-12-14	Allergan, Inc.	Enhanced bimatoprost ophthalmic solution
JP5252787B2 (ja) *	2005-08-02	2013-07-31	参天製薬株式会社	熱的に不安定な薬物の分解抑制方法
EP1916002B1 (en) *	2005-08-02	2014-03-05	Santen Pharmaceutical Co., Ltd.	Method for prevention of degradation of thermally unstable substance
JP2007099647A (ja) *	2005-09-30	2007-04-19	Kobayashi Pharmaceut Co Ltd	粘膜適用組成物
US8168206B1 (en)	2005-10-06	2012-05-01	Allergan, Inc.	Animal protein-free pharmaceutical compositions
BRPI0708891A2 (pt) *	2006-03-13	2011-06-28	R Tech Ueno Ltd	composição aquosa
US8466174B2 (en) *	2006-03-17	2013-06-18	Johnson & Johnson Vision Care, Inc.	Methods for stabilizing oxidatively unstable compositions
CA2666316A1 (en) *	2006-10-31	2008-05-08	Alcon Research, Ltd.	Pai-1 binding modulators for the treatment of ocular disorders
US20100120908A1 (en) *	2007-02-07	2010-05-13	Teika Pharmaceutical Co., Ltd	Eye drop preparation comprising latanoprost
JP2009073788A (ja) *	2007-09-21	2009-04-09	Teika Seiyaku Kk	イソプロピルウノプロストン含有眼用組成物
EA019867B1 (ru) *	2007-10-08	2014-06-30	Фовея Фармасьютикалс	Водные офтальмологические препараты
US20090232763A1 (en) *	2008-03-17	2009-09-17	Kabra Bhagwati P	Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh)	2008-03-17	2016-08-11	愛爾康研究有限公司	具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en)	2008-05-30	2009-12-02	Santen Pharmaceutical Co., Ltd	Method and composition for treating ocular hypertension and glaucoma
US8952051B2 (en) *	2009-11-05	2015-02-10	Allergan, Inc.	Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
JP2014510709A (ja) *	2011-04-12	2014-05-01	株式会社アールテック・ウエノ	眼科用水性組成物
US20130029919A1 (en) *	2011-07-26	2013-01-31	Allergan, Inc.	Two part formulation system for opthalmic delivery
EP2567689A1 (en)	2011-09-12	2013-03-13	Visiotact Pharma	Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en)	2011-10-06	2015-02-17	Allergan, Inc.	Compositions for the treatment of dry eye
CN108969482A (zh)	2011-12-07	2018-12-11	阿勒根公司	用盐敏性乳液体系对人泪液膜进行有效脂质递送
US9907826B2 (en)	2011-12-07	2018-03-06	Allergan, Inc.	Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
AU2015353701B2 (en)	2014-11-25	2021-03-25	Allergan, Inc.	Stabilized omega-3 ophthalmic compositions
AU2019343188A1 (en) *	2018-09-21	2021-05-20	Aufbau Medical Innovations Limited	Compositions and methods for glaucoma
WO2020210784A1 (en)	2019-04-12	2020-10-15	Ecolab Usa Inc.	Antimicrobial multi-purpose cleaner and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE91419T1 (de) *	1990-05-22	1993-07-15	R Tech Ueno Ltd	Synergistische kombination zur ophthalmischen verwendung.
US5767154A (en) *	1991-02-07	1998-06-16	Allergan	5-trans-prostaglandins of the F series and their use as ocular hypotensives
IE920397A1 (en) *	1991-02-07	1992-08-12	Allergan Inc	2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives
WO1995030420A1 (en) *	1994-05-06	1995-11-16	Alcon Laboratories, Inc.	Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5631287A (en) †	1994-12-22	1997-05-20	Alcon Laboratories, Inc.	Storage-stable prostaglandin compositions
US5558876A (en) *	1995-03-29	1996-09-24	Alcon Laboratories, Inc.	Topical ophthalmic acidic drug formulations
AR002194A1 (es) *	1997-03-17	1998-01-07	Sanchez Reynaldo Alemany	Instrumento computarizado para el analisis del movimiento.

1996
- 1996-06-03 AR ARP960102868A patent/AR002194A1/es unknown
1998
- 1998-03-09 MY MYPI98001017A patent/MY122237A/en unknown
- 1998-03-13 BR BRPI9816218A patent/BRPI9816218B1/pt not_active IP Right Cessation
- 1998-03-13 ES ES98916948T patent/ES2214706T5/es not_active Expired - Lifetime
- 1998-03-13 AT AT98916948T patent/ATE257385T1/de active
- 1998-03-13 RU RU99121641/14A patent/RU2197970C2/ru not_active IP Right Cessation
- 1998-03-13 AR ARP980101150A patent/AR011192A1/es not_active Application Discontinuation
- 1998-03-13 CN CNB988030195A patent/CN1236775C/zh not_active Expired - Fee Related
- 1998-03-13 EP EP98916948A patent/EP0969846B2/en not_active Expired - Lifetime
- 1998-03-13 ID IDW991029A patent/ID22389A/id unknown
- 1998-03-13 BR BR9808016-4A patent/BR9808016A/pt not_active Application Discontinuation
- 1998-03-13 KR KR1019997008431A patent/KR100555818B1/ko not_active IP Right Cessation
- 1998-03-13 NZ NZ337322A patent/NZ337322A/en not_active IP Right Cessation
- 1998-03-13 DE DE69820997T patent/DE69820997T3/de not_active Expired - Lifetime
- 1998-03-13 HU HU0002194A patent/HU228896B1/hu not_active IP Right Cessation
- 1998-03-13 PT PT98916948T patent/PT969846E/pt unknown
- 1998-03-13 EE EEP199900410A patent/EE04091B1/xx not_active IP Right Cessation
- 1998-03-13 UA UA99095110A patent/UA63938C2/uk unknown
- 1998-03-13 AU AU70353/98A patent/AU738781B2/en not_active Ceased
- 1998-03-13 PE PE1998000177A patent/PE61899A1/es not_active Application Discontinuation
- 1998-03-13 PL PL335168A patent/PL197509B1/pl unknown
- 1998-03-13 IL IL13104198A patent/IL131041A0/xx not_active IP Right Cessation
- 1998-03-13 SI SI9830616T patent/SI0969846T2/sl unknown
- 1998-03-13 WO PCT/EP1998/001483 patent/WO1998041208A1/en active IP Right Grant
- 1998-03-13 JP JP54012698A patent/JP4920124B2/ja not_active Expired - Lifetime
- 1998-03-13 CZ CZ0325799A patent/CZ299833B6/cs not_active IP Right Cessation
- 1998-03-13 CO CO98014184A patent/CO4940427A1/es unknown
- 1998-03-13 DK DK98916948.7T patent/DK0969846T4/da active
- 1998-03-13 CA CA002280089A patent/CA2280089C/en not_active Expired - Fee Related
- 1998-03-16 TW TW087103809A patent/TW527187B/zh not_active IP Right Cessation
- 1998-03-16 ZA ZA982188A patent/ZA982188B/xx unknown
1999
- 1999-09-16 NO NO19994481A patent/NO327713B1/no not_active IP Right Cessation
2000
- 2000-07-11 HK HK00104263A patent/HK1026841A1/xx not_active IP Right Cessation
2005
- 2005-05-26 CY CY0500033A patent/CY2526B1/xx unknown
2009
- 2009-09-16 CL CL2009001870A patent/CL2009001870A1/es unknown
- 2009-10-09 JP JP2009235214A patent/JP2010043110A/ja active Pending

Also Published As

Publication number	Publication date
CZ325799A3 (cs)	2000-01-12
SI0969846T1 (en)	2004-06-30
CA2280089C (en)	2009-03-03
DK0969846T4 (da)	2010-12-20
ID22389A (id)	1999-10-07
EE9900410A (et)	2000-04-17
CN1249687A (zh)	2000-04-05
NZ337322A (en)	2001-05-25
CY2526B1 (en)	2006-02-08
MY122237A (en)	2006-04-29
BR9808016A (pt)	2000-03-08
EE04091B1 (et)	2003-08-15
PE61899A1 (es)	1999-06-30
JP2010043110A (ja)	2010-02-25
AR011192A1 (es)	2000-08-02
KR20000076330A (ko)	2000-12-26
AU738781B2 (en)	2001-09-27
JP4920124B2 (ja)	2012-04-18
CO4940427A1 (es)	2000-07-24
ATE257385T1 (de)	2004-01-15
EP0969846B2 (en)	2010-08-25
HUP0002194A3 (en)	2012-08-28
HU228896B1 (en)	2013-06-28
ES2214706T5 (es)	2011-02-02
CN1236775C (zh)	2006-01-18
DE69820997T2 (de)	2004-12-09
HK1026841A1 (en)	2000-12-29
DK0969846T3 (da)	2004-04-13
PL335168A1 (en)	2000-04-10
EP0969846B1 (en)	2004-01-07
AR002194A1 (es)	1998-01-07
JP2001515502A (ja)	2001-09-18
EP0969846A1 (en)	2000-01-12
PT969846E (pt)	2004-05-31
PL197509B1 (pl)	2008-04-30
SI0969846T2 (sl)	2010-12-31
BRPI9816218B1 (pt)	2016-04-12
AU7035398A (en)	1998-10-12
ES2214706T3 (es)	2004-09-16
ZA982188B (en)	1998-09-17
DE69820997D1 (de)	2004-02-12
UA63938C2 (uk)	2004-02-16
TW527187B (en)	2003-04-11
CL2009001870A1 (es)	2010-01-22
CZ299833B6 (cs)	2008-12-10
CA2280089A1 (en)	1998-09-24
KR100555818B1 (ko)	2006-03-03
DE69820997T3 (de)	2011-10-06
NO994481D0 (no)	1999-09-16
NO994481L (no)	1999-09-16
RU2197970C2 (ru)	2003-02-10
WO1998041208A1 (en)	1998-09-24
IL131041A0 (en)	2001-01-28
HUP0002194A2 (hu)	2000-12-28

Publication	Publication Date	Title
EP0969846B1 (en)	2004-01-07	Compositions and methods for reducing ocular hypertension
US6770675B2 (en)	2004-08-03	Compositions and methods for reducing ocular hypertension
CA2502437C (en)	2012-07-17	Method and composition containing latanoprost for treating ocular hypertension and glaucoma
Shah et al.	2000	Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma
EP0473159B1 (en)	1995-03-08	Stable aqueous preparation
US5607698A (en)	1997-03-04	Method of preserving ophthalmic solution and compositions therefor
AU695699B2 (en)	1998-08-20	Non-steroidal anti-inflammatory ophthalmic suspensions
EP0706802B1 (en)	2004-03-24	A method of preserving ophthalmic solutions and compositions therefor
US20110124734A1 (en)	2011-05-26	N-halogenated amino acid formulations and methods for cleaning and disinfection
CA2146006C (en)	2004-10-12	Use of ergoline derivatives for the treatment of glaucoma
JP2003171276A (ja)	2003-06-17	眼精疲労改善眼科用組成物
JP2002316926A (ja)	2002-10-31	コンタクトレンズ用眼科用組成物及び眼刺激性の緩和方法
US6232343B1 (en)	2001-05-15	Ophthalmic preparations
GB2100599A (en)	1983-01-06	Pharmaceutical preparation for treating glaucoma and ocular hypertension
RU2434633C2 (ru)	2011-11-27	Фармацевтические препаративные формы латрункулина
WO2003020283A2 (en)	2003-03-13	Method for treating diabetic retinopathy
CA2076023A1 (en)	1991-09-20	Use of 5-trans prostaglandin f as an ocular hypotensive agent

Legal Events

Date	Code	Title	Description
2015-10-26	MM1K	Lapsed by not paying the annual fees